Cargando…
Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus
Appropriate tools are necessary for predicting cardiovascular events in patients with diabetes mellitus because of their high incidence. In this study, we assessed whether a combination of brain natriuretic peptide (BNP) and C-reactive protein (CRP) measurement were useful prognosticators in patient...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291340/ https://www.ncbi.nlm.nih.gov/pubmed/17969372 |
_version_ | 1782152449896742912 |
---|---|
author | Tsuruda, Toshihiro Kato, Johji Sumi, Takahiro Mishima, Kazuya Masuyama, Hiroyuki Nakao, Hiroyuki Imamura, Takuroh Eto, Tanenao Kitamura, Kazuo |
author_facet | Tsuruda, Toshihiro Kato, Johji Sumi, Takahiro Mishima, Kazuya Masuyama, Hiroyuki Nakao, Hiroyuki Imamura, Takuroh Eto, Tanenao Kitamura, Kazuo |
author_sort | Tsuruda, Toshihiro |
collection | PubMed |
description | Appropriate tools are necessary for predicting cardiovascular events in patients with diabetes mellitus because of their high incidence. In this study, we assessed whether a combination of brain natriuretic peptide (BNP) and C-reactive protein (CRP) measurement were useful prognosticators in patients with type 2 diabetes mellitus. One hundred and nine patients with type 2 diabetes mellitus, aged 52 to 93 years, were examined at outpatient clinics for blood, urinary samples, and echocardiography. They were then followed prospectively. During the average follow-up period of 30 months (range, 3 to 37), 15 patients (14%) had cardiovascular events: This was the first event in 5 patients and a recurrence in 10. Cox regression analysis showed that the past event (hazard ratio [HR] 4.819 [95% confidence interval (CI): 1.299–17.881]; p = 0.019) and plasma BNP level (HR 1.007 [95% CI: 1.002–1.012]; p = 0.010] were independently significant factors for the cardiovascular events during the follow-up period. Patients with plasma BNP ≥53 pg/mL and CRP ≥0.95 mg/dL demonstrated the highest incidence in cardiovascular event, compared to those categorized into either or both low levels of BNP and CRP. This study suggests that combination of plasma BNP and CRP measurement provides the additive prognostic information of cardiovascular events in patients with type 2 diabetes mellitus. |
format | Text |
id | pubmed-2291340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-22913402008-04-22 Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus Tsuruda, Toshihiro Kato, Johji Sumi, Takahiro Mishima, Kazuya Masuyama, Hiroyuki Nakao, Hiroyuki Imamura, Takuroh Eto, Tanenao Kitamura, Kazuo Vasc Health Risk Manag Original Research Appropriate tools are necessary for predicting cardiovascular events in patients with diabetes mellitus because of their high incidence. In this study, we assessed whether a combination of brain natriuretic peptide (BNP) and C-reactive protein (CRP) measurement were useful prognosticators in patients with type 2 diabetes mellitus. One hundred and nine patients with type 2 diabetes mellitus, aged 52 to 93 years, were examined at outpatient clinics for blood, urinary samples, and echocardiography. They were then followed prospectively. During the average follow-up period of 30 months (range, 3 to 37), 15 patients (14%) had cardiovascular events: This was the first event in 5 patients and a recurrence in 10. Cox regression analysis showed that the past event (hazard ratio [HR] 4.819 [95% confidence interval (CI): 1.299–17.881]; p = 0.019) and plasma BNP level (HR 1.007 [95% CI: 1.002–1.012]; p = 0.010] were independently significant factors for the cardiovascular events during the follow-up period. Patients with plasma BNP ≥53 pg/mL and CRP ≥0.95 mg/dL demonstrated the highest incidence in cardiovascular event, compared to those categorized into either or both low levels of BNP and CRP. This study suggests that combination of plasma BNP and CRP measurement provides the additive prognostic information of cardiovascular events in patients with type 2 diabetes mellitus. Dove Medical Press 2007-08 /pmc/articles/PMC2291340/ /pubmed/17969372 Text en |
spellingShingle | Original Research Tsuruda, Toshihiro Kato, Johji Sumi, Takahiro Mishima, Kazuya Masuyama, Hiroyuki Nakao, Hiroyuki Imamura, Takuroh Eto, Tanenao Kitamura, Kazuo Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus |
title | Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus |
title_full | Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus |
title_fullStr | Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus |
title_full_unstemmed | Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus |
title_short | Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus |
title_sort | combined use of brain natriuretic peptide and c-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291340/ https://www.ncbi.nlm.nih.gov/pubmed/17969372 |
work_keys_str_mv | AT tsurudatoshihiro combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus AT katojohji combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus AT sumitakahiro combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus AT mishimakazuya combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus AT masuyamahiroyuki combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus AT nakaohiroyuki combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus AT imamuratakuroh combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus AT etotanenao combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus AT kitamurakazuo combineduseofbrainnatriureticpeptideandcreactiveproteinforpredictingcardiovascularriskinoutpatientswithtype2diabetesmellitus |